share_log

AstraZeneca | 6-K: Enhertu Approved in the US as First Tumour-agnostic HER2-directed Therapy for Previously Treated Patients with Metastatic HER2-positive solid Tumours

SEC announcement ·  Apr 8 06:17
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more